329 related articles for article (PubMed ID: 14583762)
21. Thyroid adenomas after solid cancer in childhood.
Haddy N; El-Fayech C; Guibout C; Adjadj E; Thomas-Teinturier C; Oberlin O; Veres C; Pacquement H; Jackson A; Munzer M; N'Guyen TD; Bondiau PY; Berchery D; Laprie A; Bridier A; Lefkopoulos D; Schlumberger M; Rubino C; Diallo I; de Vathaire F
Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):e209-15. PubMed ID: 22672756
[TBL] [Abstract][Full Text] [Related]
22. Risk of thyroid cancer in survivors of childhood cancer: results from the British Childhood Cancer Survivor Study.
Taylor AJ; Croft AP; Palace AM; Winter DL; Reulen RC; Stiller CA; Stevens MC; Hawkins MM
Int J Cancer; 2009 Nov; 125(10):2400-5. PubMed ID: 19610069
[TBL] [Abstract][Full Text] [Related]
23. Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden.
Dickman PW; Holm LE; Lundell G; Boice JD; Hall P
Int J Cancer; 2003 Sep; 106(4):580-587. PubMed ID: 12845656
[TBL] [Abstract][Full Text] [Related]
24. Risk of Breast Cancer in Patients with Thyroid Cancer Receiving or Not Receiving 131I Treatment: A Nationwide Population-Based Cohort Study.
Lin CY; Lin CL; Huang WS; Kao CH
J Nucl Med; 2016 May; 57(5):685-90. PubMed ID: 26719377
[TBL] [Abstract][Full Text] [Related]
25. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
[TBL] [Abstract][Full Text] [Related]
26. Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.
Kumagai A; Reiners C; Drozd V; Yamashita S
Endocr J; 2007 Dec; 54(6):839-47. PubMed ID: 17938505
[TBL] [Abstract][Full Text] [Related]
27. The carcinogenic effects of radioiodine therapy for thyroid carcinoma.
de Vathaire F
Nat Clin Pract Endocrinol Metab; 2008 Apr; 4(4):180-1. PubMed ID: 18283326
[No Abstract] [Full Text] [Related]
28. Risk of second malignancies among survivors of pediatric thyroid cancer.
Adly MH; Sobhy M; Rezk MA; Ishak M; Afifi MA; Shafie AE; Ali MA; Zekri W; Alfaar AS; Rashed WM
Int J Clin Oncol; 2018 Aug; 23(4):625-633. PubMed ID: 29492793
[TBL] [Abstract][Full Text] [Related]
29. Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study.
Piscopo L; Volpe F; Nappi C; Zampella E; Manganelli M; Matrisciano F; Totaro P; Pace L; Maurea S; Cuocolo A; Klain M
Curr Oncol; 2022 Dec; 30(1):37-44. PubMed ID: 36661652
[TBL] [Abstract][Full Text] [Related]
30. Second primary malignancies induced by radioactive iodine treatment of differentiated thyroid carcinoma - a critical review and evaluation of the existing evidence.
Reinecke MJ; Ahlers G; Burchert A; Eilsberger F; Flux GD; Marlowe RJ; Mueller HH; Reiners C; Rohde F; van Santen HM; Luster M
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3247-3256. PubMed ID: 35320386
[TBL] [Abstract][Full Text] [Related]
31. Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer.
Kim KJ; Kim KJ; Choi J; Kim NH; Kim SG
J Natl Cancer Inst; 2023 Jun; 115(6):695-702. PubMed ID: 36821433
[TBL] [Abstract][Full Text] [Related]
32. Subsequent malignancies in patients treated with 131-iodine for thyroid cancer.
Glanzmann C
Strahlenther Onkol; 1992 Jun; 168(6):337-43. PubMed ID: 1621212
[TBL] [Abstract][Full Text] [Related]
33. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations.
Brown AP; Neeley ES; Werner T; Soisson AP; Burt RW; Gaffney DK
Int J Radiat Oncol Biol Phys; 2010 Sep; 78(1):127-35. PubMed ID: 19910129
[TBL] [Abstract][Full Text] [Related]
34. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
35. Risk of second bone sarcoma following childhood cancer: role of radiation therapy treatment.
Schwartz B; Benadjaoud MA; Cléro E; Haddy N; El-Fayech C; Guibout C; Teinturier C; Oberlin O; Veres C; Pacquement H; Munzer M; N'guyen TD; Bondiau PY; Berchery D; Laprie A; Hawkins M; Winter D; Lefkopoulos D; Chavaudra J; Rubino C; Diallo I; Bénichou J; de Vathaire F
Radiat Environ Biophys; 2014 May; 53(2):381-90. PubMed ID: 24419490
[TBL] [Abstract][Full Text] [Related]
36. Salivary gland malignancy and radioiodine therapy for thyroid cancer.
Klubo-Gwiezdzinska J; Van Nostrand D; Burman KD; Vasko V; Chia S; Deng T; Kulkarni K; Wartofsky L
Thyroid; 2010 Jun; 20(6):647-51. PubMed ID: 20470209
[TBL] [Abstract][Full Text] [Related]
37. Risk of second primary breast cancer after radioactive iodine treatment in thyroid cancer: a systematic review and meta-analysis.
Zhang Y; Liang J; Li H; Cong H; Lin Y
Nucl Med Commun; 2016 Feb; 37(2):110-5. PubMed ID: 26513055
[TBL] [Abstract][Full Text] [Related]
38. Thyroid adenomas and carcinomas following radiotherapy for a hemangioma during infancy.
Haddy N; Andriamboavonjy T; Paoletti C; Dondon MG; Mousannif A; Shamsaldin A; Doyon F; Labbé M; Robert C; Avril MF; Fragu P; Eschwege F; Chavaudra J; Schvartz C; Lefkopoulos D; Schlumberger M; Diallo I; de Vathaire F
Radiother Oncol; 2009 Nov; 93(2):377-82. PubMed ID: 19515442
[TBL] [Abstract][Full Text] [Related]
39. Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients.
Mei X; Yao X; Feng F; Cheng W; Wang H
BMC Cancer; 2021 May; 21(1):543. PubMed ID: 33980182
[TBL] [Abstract][Full Text] [Related]
40. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics.
Kim S; Bang JI; Boo D; Kim B; Choi IY; Ko S; Yoo IR; Kim K; Kim J; Joo Y; Ryoo HG; Paeng JC; Park JM; Jang W; Kim B; Chung Y; Yang D; Yoo S; Lee HY
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3547-3556. PubMed ID: 35362796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
